GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Sera Prognostics
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. Its stock price reflects the potential of its tests, but also the challenging path to widespread clinical adoption and reimbursement from insurers.
Share prices of companies in the market segment - Reproduction
Sera Prognostics specializes in developing tests to predict the risk of preterm birth and other pregnancy complications. We classify the company as part of the Reproduction sector, as its technologies are aimed at improving the health of mothers and children. The chart below shows the overall dynamics of this important healthcare segment.
Broad Market Index - GURU.Markets
Sera Prognostics is a women's health company that has developed a test to predict the risk of preterm birth. Its innovation has earned it a spot in the GURU.Markets index. The chart below compares its performance with the overall market.
Change in the price of a company, segment, and market as a whole per day
SERA - Daily change in the company's share price Sera Prognostics
For Sera Prognostics, which operates in the women's health field, daily price change is a measure of volatility associated with innovative medicine. This indicator reflects sensitivity to scientific publications and the commercial success of tests, making it an important element of analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Reproduction
Sera Prognostics, Inc. is a women's health company. This chart illustrates the high volatility of the MedTech sector. Comparing it to SERA, which focuses on predictive pregnancy tests, helps assess how sensitive its business is to the introduction of new technologies.
Daily change in the price of a broad market stock, index - GURU.Markets
Sera Prognostics develops tests to predict the risk of preterm birth. It's an innovative women's health company whose stock is driven by clinical data and the acceptance of its tests by the medical community. Its unique story is part of a broader mosaic of market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Sera Prognostics
Sera Prognostics' year-over-year performance is the story of the introduction of its prenatal test for predicting the risk of premature birth. Its 12-month market cap depends entirely on the success of commercializing this test. Each new contract with an insurance company or major hospital network is a fundamental step toward widespread adoption of its technology.
Annual dynamics of market capitalization of the market segment - Reproduction
Sera Prognostics, Inc. is a women's health company that has developed a test to predict the risk of preterm birth. Its success depends on the widespread adoption of this innovative test. The chart below shows how the market views the commercial potential of its technology and its path to profitability.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sera, with its test for predicting preterm labor, is a growth story in medicine. Its stock price is determined not by the economy, but by the speed of adoption of its technology by doctors and the insurance system. The chart reflects the potential of this breakthrough technology in the vast obstetrics market, regardless of the economic climate.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Sera Prognostics
Sera Prognostics develops diagnostic tests for predicting pregnancy risks. Its monthly growth reflects progress in commercializing its tests. Key drivers include the growing number of physicians using the test and, more importantly, receiving approval from insurance companies for coverage.
Monthly dynamics of market capitalization of the market segment - Reproduction
Sera Prognostics is a women's health company that developed the world's first prenatal blood test to predict the risk of preterm birth. The graph below illustrates the overall dynamics in the reproductive medicine sector, where new diagnostic tools have the potential to radically transform patient care.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Women's health and diagnostics stocks are betting on the future of personalized medicine. The chart below shows investors' overall risk appetite. Is Sera Prognostics moving in sync with the market's growth, or is its commercial success creating its own trend?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Sera Prognostics
The weekly performance of Sera Prognostics reflects efforts to predict pregnancy risks. This diagnostics company's stock price is responding to the introduction of its tests for predicting preterm birth and data confirming their clinical and economic value.
Weekly dynamics of market capitalization of the market segment - Reproduction
Sera Prognostics develops diagnostic tests to predict pregnancy risks. The company operates at the intersection of biotech and women's health. The chart below shows whether Sera's share price fluctuations reflect its unique clinical data and commercial success or whether they reflect broader trends in the medical diagnostics sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Sera Prognostics is a company in the medical diagnostics sector. Shares of such companies may be less dependent on general economic cycles. This chart will help us understand: are Sera shares stuck in a world of clinical trials and the introduction of new tests, or are their stock prices still influenced by overall market conditions?
Market capitalization of the company, segment and market as a whole
SERA - Market capitalization of the company Sera Prognostics
The market capitalization chart of Sera Prognostics tells the story of the company that developed the world's first prenatal test for predicting the risk of premature birth. Its decline on the chart tells the story of the test's difficult path to commercialization and acceptance by the medical community and insurance companies. This dynamic reflects the struggle to create a new standard in maternity care.
SERA - Share of the company's market capitalization Sera Prognostics within the market segment - Reproduction
Sera Prognostics is a women's health company specializing in the development of diagnostic tests to predict the risk of preterm birth. Its market share reflects the potential of its unique technology. The chart below shows how the market assesses its chances of widespread adoption of this test, crucial for maternal and child health.
Market capitalization of the market segment - Reproduction
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. The graph below shows the market capitalization of this innovative sector. Its dynamics reflect the potential of predictive medicine to improve pregnancy outcomes and the health of mothers and children.
Market capitalization of all companies included in a broad market index - GURU.Markets
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. Its capitalization is a bet on the potential of predictive medicine to improve the health of mothers and children. Its growth reflects how new diagnostic tools are finding their place in medical practice.
Book value capitalization of the company, segment and market as a whole
SERA - Book value capitalization of the company Sera Prognostics
Sera Prognostics' book value is the capital invested in the commercialization of a unique blood test for predicting the risk of preterm birth. This is a tangible, scientific foundation for improving maternal and child health. How has this innovative diagnostic asset changed? The chart below shows its dynamics.
SERA - Share of the company's book capitalization Sera Prognostics within the market segment - Reproduction
Sera Prognostics developed a test to predict the risk of preterm birth, which requires certified laboratories. The graph shows the proportion of these tangible assets, reflecting the physical foundation on which its diagnostic service is built.
Market segment balance sheet capitalization - Reproduction
Sera Prognostics develops diagnostic tests for pregnant women. It's a knowledge-intensive business, where laboratories are important, but the main value lies in technology. The book value chart will show the financial basis on which its innovations in women's health are built.
Book value of all companies included in the broad market index - GURU.Markets
Sera Prognostics develops tests to predict pregnancy risks. Its book value is represented by its laboratories, diagnostic equipment, and extensive biobank. The chart shows the material foundation upon which technologies are built to improve maternal and child health.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Sera Prognostics
Sera Prognostics owns laboratories, but its value lies in its unique pregnancy test. The chart shows the premium the market is paying for this test's potential to become a standard in obstetrics. This is a measure of intellectual property, not equipment.
Market to book capitalization ratio in a market segment - Reproduction
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. Its value lies in its unique technology and potential to improve maternal and child health. The chart shows how confident investors are in the commercial success of its tests.
Market to book capitalization ratio for the market as a whole
Sera Prognostics has developed a blood test to predict the risk of preterm birth. The company's value lies in its unique diagnostic technology. This chart shows the overall market valuation, but how do investors value a company whose product can help doctors better manage pregnancies and save newborn lives?
Debts of the company, segment and market as a whole
SERA - Company debts Sera Prognostics
Sera Prognostics, a diagnostic company focused on maternal and child health, is in the commercialization phase. Its financial strategy is focused on market penetration. The capital is being used to finance large-scale efforts to train physicians and integrate its tests into standard medical practice.
Market segment debts - Reproduction
Sera Prognostics develops diagnostic tests to predict the risk of pregnancy complications. This is an innovative area of personalized medicine. This chart shows how the company is funding the commercialization of its tests and research for their wider implementation in clinical practice.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Sera Prognostics
Sera Prognostics develops diagnostic tests for predicting pregnancy risks. This chart shows how the company finances its innovative developments, which require extensive clinical validation. For a medical diagnostics company, debt reflects the cost of achieving commercialization and acceptance by the medical community.
Market segment debt to market segment book capitalization - Reproduction
Sera Prognostics develops diagnostic tests to predict pregnancy risks, such as preterm birth. This chart shows the overall debt burden in the reproductive medicine and diagnostics sector. It helps understand how companies finance the launch of new tests and the clinical trials needed to validate them.
Debt to book value of all companies in the market
Sera Prognostics develops diagnostic tests for predicting pregnancy risks. It is an innovative medical company whose value lies in its unique technology. This chart, reflecting debt trends in the economy, demonstrates how its business model, dependent on product success and medical acceptance, differs from traditional industries.
P/E of the company, segment and market as a whole
P/E - Sera Prognostics
For Sera Prognostics, a company specializing in preterm birth risk diagnostics, this chart shows the valuation of its innovative technology. The multiple reflects investors' belief that its tests will become standard in obstetrics, helping improve outcomes for mothers and babies and reduce healthcare costs.
P/E of the market segment - Reproduction
Obstetric diagnostics, Sera Prognostics' specialty, is a new field. This chart shows the average rating for medical technology companies. It helps us understand that Sera, with its test for predicting the risk of preterm birth, is being evaluated based on its potential to transform medical practice and reduce healthcare costs.
P/E of the market as a whole
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth, a critical issue in obstetrics. The company's success depends on the widespread adoption of its tests. This chart, reflecting sentiment in the healthcare sector, helps understand how the market views the commercial potential of breakthrough diagnostic tools like Sera's tests.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Sera Prognostics
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. This chart reflects investor expectations for the adoption of its tests in standard obstetric practice. This growth reflects a bet that its product will help improve pregnancy outcomes and reduce healthcare costs.
%20P%2FE%20Sera%20Prognostics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Sera-Prognostics&v=1772558768053 "Chart of the company's future (projected) P/E Sera Prognostics")
Future (projected) P/E of the market segment - Reproduction
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. This chart shows the average profitability expectations for the sector. It helps understand how highly the market values the potential of its tests to improve pregnancy outcomes and reduce healthcare costs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Reproduction&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Reproduction&v=1772558768075 "Future (projected) P/E graph of the market segment - Reproduction")
Future (projected) P/E of the market as a whole
Sera Prognostics, Inc. is a women's health company specializing in diagnostic tests to predict the risk of preterm birth. This chart demonstrates investor appetite for medical innovation. For a company solving a critical problem in obstetrics, it reflects the market's willingness to invest in breakthrough diagnostic technologies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772558768078 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Sera Prognostics
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. Commercial success, as illustrated by this graph, depends on physician acceptance of its tests and insurance reimbursement. The graph reflects the journey of this innovative women's health product from development to widespread clinical use.
Profit of companies in the market segment - Reproduction
Sera Prognostics is a women's health company specializing in diagnostic tests to predict the risk of preterm birth. Its PreTRM test helps doctors identify risk groups. This graph illustrates how innovations in prenatal diagnostics can improve pregnancy outcomes and create a new, lucrative market in the healthcare sector.
Overall market profit
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. Demand for its innovative products depends on their acceptance by the medical community and coverage by insurance companies. The company's growth reflects the trend toward personalized and predictive medicine, which is an important part of the evolving healthcare economy.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Sera Prognostics
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. The profit forecast in this chart reflects analysts' expectations for the clinical adoption of its tests and reimbursement from insurance companies.
%20profit%20of%20the%20company%20Sera%20Prognostics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Sera-Prognostics&v=1772558768177 "Graph of future (projected) profit of the company Sera Prognostics")
Future (predicted) profit of companies in the market segment - Reproduction
Sera Prognostics is a women's health company specializing in diagnostic tests for predicting the risk of preterm birth. Their flagship test is PreTRM. This graph shows the revenue projections for the reproductive health sector, allowing us to assess how successfully Sera can integrate their innovative test into standard obstetric practice.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Reproduction&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Reproduction&v=1772558768218 "Graph of future (predicted) profits of companies in a market segment - Reproduction")
Future (predicted) profit of the market as a whole
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. Demand for these innovative tests depends on their acceptance by the medical community and insurance companies. This dynamic, reflecting the state of the economy, influences healthcare system budgets and their willingness to cover new diagnostics.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772558768247 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Sera Prognostics
Sera Prognostics has developed a first-of-its-kind blood test to predict the risk of preterm birth. This chart shows how investors estimate the company's revenue, betting on widespread adoption of its predictive test. The estimate reflects the potential for improved pregnancy outcomes and reduced costs.
P/S market segment - Reproduction
Sera Prognostics is a leader in predicting maternal and child health risks. The company developed the PreTRM test for early detection of preterm birth risk. This chart shows the average price-to-sales ratio for the medical technology sector, reflecting how the market perceives the potential of this unique diagnostic product.
P/S of the market as a whole
Sera Prognostics is a women's health company that has developed and commercialized a test to predict the risk of preterm birth. The company aims to improve pregnancy outcomes. This overall market valuation chart helps understand how investors value companies in the diagnostics sector that offer breakthrough tests that have not yet become standard.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Sera Prognostics
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. This chart shows the company's estimated future sales. It reflects investor expectations for the adoption of its tests in standard obstetric practice to improve pregnancy outcomes.
%20P%2FS%20Sera%20Prognostics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Sera-Prognostics&v=1772558768321 "The graph of the company's future (projected) P/S Sera Prognostics")
Future (projected) P/S of the market segment - Reproduction
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. Its flagship test, PreTRM, helps doctors identify women at increased risk. This chart shows how investors estimate the future revenue potential of its innovative tests in women's health and reproductive medicine.
%20P%2FS%20market%20segment%20graph%20-%20Reproduction&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Reproduction&v=1772558768333 "Future (projected) P/S market segment graph - Reproduction")
Future (projected) P/S of the market as a whole
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. The company's growth depends on the adoption of its tests in clinical practice. This general expectations chart for SERA is not a direct driver. Demand for its products is determined by their clinical value and ability to improve pregnancy outcomes, not by economic cycles.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772558768362 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Sera Prognostics
This graph shows the commercialization path of an innovative diagnostic test. For Sera Prognostics, it reflects initial revenues from the introduction of their PreTRM® test, which helps predict the risk of preterm birth. The trend is an indicator of the acceptance of this method in obstetric practice.
Sales of companies in the market segment - Reproduction
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. Its technology is aimed at improving the health of mothers and children. This graph shows the growth of the testing market. The introduction of predictive tests like Sera's could create a new standard in obstetrics and significantly increase the diagnostic market.
Overall market sales
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. The company works at the intersection of medicine and data, solving a crucial problem in obstetrics. Demand for its tests reflects the trend toward predictive and personalized medicine, which is becoming an increasingly important part of modern healthcare.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Sera Prognostics
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. The company's future sales depend on the adoption of its tests in obstetric practice and reimbursement from insurance companies.
%20sales%20of%20the%20company%20Sera%20Prognostics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Sera-Prognostics&v=1772558768450 "Schedule of future (projected) sales of the company Sera Prognostics")
Future (projected) sales of companies in the market segment - Reproduction
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. The forecast for the reproductive medicine and diagnostics sector demonstrates the demand for innovation. The graph reflects the significant need for tools that can improve pregnancy outcomes and reduce healthcare costs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Reproduction&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Reproduction&v=1772558768466 "Schedule of future (projected) sales of companies in the market segment - Reproduction")
Future (projected) sales of the market as a whole
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. Demand for its products is driven by medical needs and acceptance by the medical community. This general economic activity pattern does not affect the demand for such tests, but it may impact insurance coverage and healthcare budgets.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772558768484 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Sera Prognostics
Sera Prognostics is a diagnostic company specializing in tests for predicting the risk of preterm birth. Its financial success depends on the widespread adoption of this test in obstetric practice. This chart illustrates the company's complex economics: balancing high research and marketing costs with growing sales revenue.
Market segment marginality - Reproduction
Sera Prognostics specializes in developing diagnostic tests to predict pregnancy risks, such as preterm birth. Profitability will depend on the adoption of its tests in standard medical practice. This metric reflects the company's operational structure at the commercialization stage compared to other diagnostic companies.
Market marginality as a whole
Sera Prognostics, Inc. is a women's health company that developed a prenatal test to predict the risk of preterm birth. This chart shows total revenue. In contrast, Sera is a story about the commercialization of a breakthrough diagnostic test. Its path to profitability depends on widespread physician acceptance and reimbursement from insurance companies.
Employees in the company, segment and market as a whole
Number of employees in the company Sera Prognostics
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. Its team consists of scientists, laboratory technicians, and sales personnel. The growth in this graph reflects efforts to introduce its PreTRM test into clinical practice. The increase in staff is necessary to support collaboration with physicians and insurance companies.
Share of the company's employees Sera Prognostics within the market segment - Reproduction
Sera Prognostics is a women's health company that developed the world's first test to predict the risk of preterm birth. This chart highlights its unique scientific niche. It reflects the percentage of scientists and biomarker specialists working in maternal and child health that Sera is engaging to promote its innovative test.
Number of employees in the market segment - Reproduction
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. This chart illustrates growth in the women's health (FemTech) sector. The company's expansion reflects the growing focus on prenatal diagnostics and the desire to use predictive analytics to improve pregnancy outcomes.
Number of employees in the market as a whole
Sera Prognostics develops tests for predicting pregnancy risks. This is an innovative field of medicine. Their growth depends not on the overall economic situation, as illustrated by this graph, but on the acceptance of their tests by the medical community and insurance companies. Successful implementation in clinical practice is the main driver for hiring.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Sera Prognostics (SERA)
Sera Prognostics has developed a first-of-its-kind prenatal blood test to predict the risk of premature birth. This chart shows how the market values this breakthrough diagnostic technology. Their high market capitalization per employee reflects the uniqueness and potential of their technology to change pregnancy care standards, not the size of their lab or sales force.
%20of%20the%20company%20Sera%20Prognostics%20(SERA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Sera-Prognostics-SERA&v=1772558768703 "Chart of market capitalization per employee (in thousands of dollars) of the company Sera Prognostics (SERA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Reproduction
Sera Prognostics develops diagnostic tests for predicting pregnancy risks. This is a cutting-edge field of medicine, where value is created through scientific discoveries. This chart illustrates how the market values the company's unique technology: the high cost per employee speaks to the great potential of its tests and intellectual property.
%20by%20market%20segment%20-%20Reproduction&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Reproduction&v=1772558768778 "Market capitalization per employee (in thousands of dollars) by market segment - Reproduction")
Market capitalization per employee (in thousands of dollars) for the overall market
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. This graph reflects the company's high employee rating, as its innovative test can solve a serious medical problem, opening a large potential market and generating significant value.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772558768799 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Sera Prognostics (SERA)
Sera Prognostics is a women's health company specializing in diagnostic tests. Their flagship product is the PreTRM test, which predicts the risk of preterm birth. It's a medtech company. This chart shows how successful the commercialization of this test is. It measures how much profit (or loss) each employee, from lab technician to salesperson, generates.
%20Chart%20Sera%20Prognostics%20(SERA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Sera-Prognostics-SERA&v=1772558768810 "Company Profit Per Employee (in thousands of dollars) Chart Sera Prognostics (SERA)")
Profit per employee (in thousands of dollars) in the market segment - Reproduction
Sera Prognostics (SERA) specializes in maternal and child health diagnostics, specifically tests to predict preterm birth. This chart represents the benchmark in the medical diagnostics sector. SERA's effectiveness depends on the acceptance of its tests by physicians and insurance companies. Their goal is to automate lab analysis to maximize profits from each test.
%20in%20the%20market%20segment%20-%20Reproduction&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Reproduction&v=1772558768820 "Chart of profit per employee (in thousands of dollars) in the market segment - Reproduction")
Profit per employee (in thousands of dollars) for the market as a whole
Sera Prognostics (SERA) specializes in maternal and child health diagnostics, specifically tests for preterm birth. It's a MedTech business that requires both R&D and strong sales. This chart shows how successful the company's commercial team is in convincing doctors and insurance companies to use their tests to generate revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772558768821 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Sera Prognostics (SERA)
Sera Prognostics develops diagnostic tests to predict pregnancy risks. This graph shows the commercialization stage of its innovative products. Growth in this metric will indicate the successful implementation of the tests in clinical practice and the company's ability to monetize its research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Sera-Prognostics-SERA&v=1772558768825 "Sales chart per company employee Sera Prognostics (SERA)")
Sales per employee in the market segment - Reproduction
Sera Prognostics is a company specializing in women's health diagnostics, specifically tests for predicting preterm birth. This metric measures how effectively their laboratories and sales teams generate revenue from each test performed. A comparison with the industry demonstrates the success of their technology's commercialization.
Sales per employee for the market as a whole
Sera Prognostics is a medical analysis company specializing in women's health. Their flagship product is the PreTRM test for predicting the risk of preterm birth. This graph shows revenue per employee, reflecting how successfully their sales team is promoting this innovative diagnostic test to physicians and insurance companies.
Short shares by company, segment and market as a whole
Shares shorted by company Sera Prognostics (SERA)
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. This chart shows bearish bets. Bearish bets may be hesitant to believe the company's test (PreTRM) will gain widespread acceptance among physicians and insurance companies, or that its predictive value is sufficient to become standard medical practice.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Sera-Prognostics-SERA&v=1772558768858 "Short Shares Chart for the Company Sera Prognostics (SERA)")
Shares shorted by market segment - Reproduction
Sera Prognostics specializes in diagnostic tests to predict pregnancy risks (such as preterm birth). This chart shows overall short positions in the medical diagnostics sector. If it's high, investors may be concerned that the entire industry will face problems receiving reimbursement from insurance companies.
Shares shorted by the overall market
Sera Prognostics (SERA) is developing tests to predict labor. This is a speculative R&D story. When this market fear indicator rises, investors' risk appetite plummets. They are unwilling to wait for approval and implementation. They sell off unprofitable shares, like SERA, whose fate depends on a single product.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Sera Prognostics (SERA)
Sera Prognostics develops diagnostic tests to predict the risk of preterm birth. Its business depends on test adoption and insurance reimbursement. A level above 70 may reflect positive reimbursement news or an increase in testing. A level below 30 indicates slow adoption or payment issues.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Sera-Prognostics-SERA&v=1772558768902 "RSI 14 indicator chart for the company's stock Sera Prognostics (SERA)")
RSI 14 Market Segment - Reproduction
Sera (SERA) is a "medtech" for *pregnant* women. They produce a *diagnostic test* (blood) that *predicts* the risk of *preterm* birth. The "Reproduction" sector thrives on R&D. RSI_14_Seg shows whether the *entire* sector is "overbought." This helps differentiate: is SERA's growth a niche or a general "hype"?
RSI 14 for the overall market
Sera Prognostics, a company developing pregnancy tests, sees this graph as a sign of the healthcare system's readiness for innovation. During periods of euphoria and budget increases, hospitals eagerly implement new, expensive tests. In times of panic and cost-cutting, they "freeze" spending, preferring older, cheaper diagnostic methods.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SERA (Sera Prognostics)
Sera Prognostics is a company specializing in maternal and child health. They have developed a test (PreTRM) to predict the risk of preterm birth. This graph shows the analysts' average 12-month forecast, reflecting their assessment of how quickly this diagnostic test will be implemented into clinical practice.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SERA-Sera-Prognostics&v=1772558768937 "A chart showing analyst consensus forecasts for the expected stock price. SERA (Sera Prognostics)")
The difference between the consensus estimate and the actual stock price SERA (Sera Prognostics)
Sera Prognostics (SERA) is a diagnostic company that developed a test (PreTRM) for predicting the risk of preterm birth. This chart shows the assessment of their technology. It measures the gap between the price and the consensus target, reflecting whether analysts believe their test will be widely adopted by doctors and insurance companies.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SERA-Sera-Prognostics&v=1772558768940 "A chart showing the difference between the consensus forecast and the actual stock price. SERA (Sera Prognostics)")
Analyst consensus forecast for stock prices by market segment - Reproduction
Sera Prognostics is a diagnostic company focused on women's health. Its flagship product (PreTRM) is a blood test for predicting the risk of preterm birth. This chart shows analysts' overall expectations for the reproductive health sector. It reflects whether experts believe in the commercialization of prenatal diagnostics.
Analysts' consensus forecast for the overall market share price
Sera Prognostics is a company specializing in reproductive health. Their flagship product is the PreTRM blood test, which predicts the risk of preterm birth. This chart shows overall market sentiment. For Sera, which operates in the protective healthcare sector, overall optimism is important, but their growth depends more on the acceptance of the test by insurance companies and doctors.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Sera Prognostics
Sera Prognostics is a MedTech company focused on maternal and child health. Their flagship product (PreTRM) is the world's first prognostic blood test that helps predict the risk of preterm birth. This graph is a summary indicator of their commercialization, reflecting their ability to convince doctors and, more importantly, insurers of the necessity of this innovative test.
AKIMA Market Segment Index - Reproduction
Sera Prognostics is a company specializing in maternal and child health. Its flagship test (PreTRM) is designed to predict the risk of preterm birth. This chart shows the average index for the reproductive medicine sector, allowing investors to assess how Sera's innovative diagnostics compares to the average.
The AKIM Index for the overall market
Sera Prognostics is a women's health company that developed a blood test (PreTRM) to predict the risk of preterm birth. This chart, reflecting the market average, is a backdrop. It helps assess how this diagnostic analysis, which influences insurance coverage, compares to overall macroeconomic trends.
